Indian Journal of PsychiatryIndian Journal of Psychiatry
Home | About us | Current Issue | Archives | Ahead of Print | Submission | Instructions | Subscribe | Advertise | Contact | Login 
    Users online: 1347 Small font sizeDefault font sizeIncrease font size Print this article Email this article Bookmark this page
Search Again
 Back
 Table of Contents
 
 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Article Access Statistics
 Reader Comments
 Email Alert
 Add to My List
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1261    
    Printed20    
    Emailed0    
    PDF Downloaded113    
    Comments [Add]    

Recommend this journal

 
ORIGINAL ARTICLE
Year : 2021  |  Volume : 63  |  Issue : 5  |  Page : 483-489

Antisuicidal efficacy of ketamine infusion in suicidal patients of depressive disorder


1 Department of Psychiatry, Shyam Shah Medical College, Rewa, Madhya Pradesh, India
2 Department of Anaesthesia, Super Specialty Hospital and Shyam Shah Medical College, Rewa, Madhya Pradesh, India

Correspondence Address:
Sunil Kumar Ahuja
Ground Floor, Mansik Rog Vibhag, Sanjay Gandhi Hospital, Rewa - 486 001, Madhya Pradesh
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/indianjpsychiatry.indianjpsychiatry_80_21

Rights and Permissions

Background: The efficacy of ketamine in the rapid alleviation of depressive and suicidal symptoms has been observed over the past few years around the globe. Exploration of rapid antisuicidal efficacy of ketamine in Indian subpopulation can be a good preventive pharmacological option for unprecedented rise in suicides in India. Aim: To assess efficacy of ketamine infusions on suicidal patients of depressive disorder. Severity of depression and suicidality were quantified daily over 1 week. Materials and Methods: This was a randomized control study, comprised sixty patients of age group 18–60 years, with a diagnosis of depressive episode, having the Modified Scale for Suicidal Ideations (MSSI) score >20 with exclusion of severe medical or surgical illness, pregnancy, and breast-feeding females. Patient were assigned to ketamine and normal saline group. Three infusions were given over 1 week on day 0, day 2, and day 4. Assessments were made at baseline using the 17-item Hamilton Depression Rating Scale (HAM-D17) and MSSI, for depression and suicidality, respectively. Assessments were repeated at 6 h after first infusion and then every day for 1 week. Results: There were significant reductions in HAM-D17 score and MSSI score within 6 h of the first dose in the ketamine group as compared to the normal saline group. Significant sustained improvement was seen on further days till 1 week in the ketamine group as compared to the normal saline group. Conclusion: Ketamine might be a reasonable choice to fulfil the efficacy gap created by the delayed antisuicidal onset of standard treatments.



[FULL TEXT] [PDF]*

        

Print this article         Email this article